A 35-year-old woman is admitted to the hospital with a 5-day history of abdominal distention and jaundice. She reports no history of fever, chills, night sweats, abdominal pain, nausea, vomiting, diarrhea, changes in urine color, change in stool color, weight loss, weight gain, or loss of appetite.

She is petite, with a body mass index of 19.4 kg/m². She has no known history of medical conditions or surgery and is not taking any medications. Her family history is unremarkable, and she denies current or past tobacco, alcohol, or illicit drug use.

■ RECENT TRAVEL
She says that during a trip to Central America several months ago, she had suffered a seizure and was taken to a local hospital, where laboratory testing revealed elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. She says that the rest of the workup at that time was normal.

About 1 week after that incident, she returned home and saw her primary care physician, who ordered further testing, which showed mild hyperbilirubinemia and mild elevation of AST and ALT levels. Her physician attributed the elevations to atovaquone, which she had been taking for malaria prophylaxis, as repeat testing 2 weeks later showed improvement in AST and ALT levels.

The patient says she returned to her normal state of health until about 5 days ago, when she noticed jaundice and abdominal distention, but without abdominal pain, dark urine, or clay-colored stools. She became concerned and went to her local hospital. Testing there noted mild elevation of AST and ALT, as well as an elevated international normalized ratio (INR) and hyperbilirubinemia. Computed tomography of the abdomen and pelvis showed hepatomegaly with possible fatty liver. Because of these results, the patient was transferred to our institution for further evaluation.

■ EVALUATION AT OUR INSTITUTION
On examination at our institution, she is afebrile, and vital signs are within normal ranges. She has bilateral scleral icterus and diffuse jaundice, but no other skin finding such as rash or spider angioma. She has no lymphadenopathy. Her abdomen is distended, with tense ascites, and her liver is tender to palpation. The tip of the spleen is not palpable.

On cardiovascular examination, there are no murmurs, rubs, or gallops, but she has jugular venous distention and +2 pitting edema of both lower extremities.

On respiratory examination, there is dullness to percussion, with slight crackles on auscultation at the right lung base. The neurologic examination is normal.

Table 1 shows the results of initial laboratory testing.

| Study                                      | Result |
|--------------------------------------------|--------|
| Abdominal ultrasonography                 |        |
| Abdominal paracentesis with ascitic fluid analysis |        |
| Chest radiography                          |        |
| Echocardiography                           |        |
| Urine protein-to-creatinine ratio          |        |

A serum-ascites albumin gradient ≥ 1.1 g/dL indicates portal hypertension

1 Which study would provide the most information on the cause of ascites?

- Abdominal ultrasonography
- Abdominal paracentesis with ascitic fluid analysis
- Chest radiography
- Echocardiography
- Urine protein-to-creatinine ratio

Abdominal paracentesis with ascitic fluid analysis is the essential study for any patient
NEW-ONSET ASCITES

It is the study that provides the most information on the cause of ascites. In our patient, abdominal paracentesis yields 1,000 mL of straw-colored ascitic fluid, and analysis shows 86 nucleated cells, 28 of which are polymorphonuclear cells, and 0 red blood cells, with negative Gram stain and culture. The ascitic albumin level is 0.85 g/dL, with an ascitic protein of 1.1 g/dL.

Abdominal ultrasonography shows a diffusely echogenic liver, no focal lesions, moderate ascites, normal portal vein flow, no intrahepatic or extrahepatic biliary duct dilation, normal kidney sizes, no hydronephrosis, and no intra-abdominal mass. Chest radiography is clear with no sign of consolidation, edema, or effusion. Echocardiography shows a normal left ventricular ejection fraction with no valvular disease or pericardial effusion. A random urine protein-creatinine ratio is normal at 0.1 (reference range < 0.2).

What is the most likely cause of her ascites based on the workup to this point?

- Cirrhosis
- Heart failure
- Nephrotic syndrome
- Portal vein thrombus
- Abdominal malignancy
- Malaria

An initial approach to ascitic fluid analysis is to calculate the serum-ascites albumin gradient (SAAG). The SAAG is calculated as the serum albumin level minus the ascitic fluid albumin level. This is useful in determining the cause of the ascites (Figure 1). A gradient of 1.1 g/dL or greater indicates portal hypertension. Common causes of portal hypertension include cirrhosis, alcoholic hepatitis, heart failure, vascular occlusion syndromes (eg, Budd-Chiari syndrome, portal vein thrombosis), idiopathic portal fibrosis, and metastatic liver disease.

If portal hypertension is present based on the SAAG, the next step is to review the ascitic protein level to help distinguish between a hepatic and a cardiac etiology of the ascites. An ascitic protein level less than 2.5 g/dL indicates a primary liver pathology (eg, cirrhosis). An ascitic protein level of 2.5 g/dL or greater typically indicates a cardiac condition (eg, heart failure, pericardial disease) with secondary congestive hepatopathy.

If the SAAG is less than 1.1 g/dL, the ascites is likely not from portal hypertension. Typical causes of a low SAAG include infection, malignancy, pancreatic ascites, and nephrotic syndrome.

In our patient, the SAAG is 1.35 g/dL (2.2 g/dL minus 0.85 g/dL), ie, elevated and due to portal hypertension. With an SAAG of 1.1 g/dL or greater and an ascitic fluid protein level less than 2.5 g/dL, in our patient, the most likely cause is cirrhosis.

### TABLE 1

Results of initial laboratory testing

| Test                          | Resulta       | Reference range |
|-------------------------------|---------------|-----------------|
| White blood cell count        | 17.3 x 10^9/L | (3.7–10.3)      |
| Neutrophil count              | 82%           |                 |
| Hemoglobin                    | 8.8 g/dL      | (11.2–15.7)     |
| Hematocrit                    | 24.0%         | (34%–45%)       |
| Platelet count                | 112 x 10^9/L  | (155–369)       |
| Sodium                        | 128 mmol/L    | (136–145)       |
| Potassium                     | 3.2 mmol/L    | (3.7–4.8)       |
| Chloride                      | 86 mg/dL      | (101–108)       |
| Blood urea nitrogen           | 16 mg/dL      | (7–21)          |
| Creatinine                    | 0.62 mg/dL    | (0.60–1.10)     |
| Glucose                       | 91 mg/dL      | (74–99)         |
| Aspartate aminotransferase    | 97 U/L        | (11–32)         |
| Alanine aminotransferase      | 24 U/L        | (8–33)          |
| Alkaline phosphatase          | 224 U/L       | (35–104)        |
| Gamma-glutamyltransferase     | 996 U/L       | (7–36)          |
| Total bilirubin               | 17.0 mg/dL    | (0.2–1.1)       |
| Total protein                 | 4.9 g/dL      | (6.3–7.9)       |
| Albumin                       | 2.2 g/dL      | (3.3–4.6)       |
| Total calcium                 | 7.3 mg/dL     | (8.9–10.2)      |
| Erythrocyte sedimentation rate| 16 mm/h       | (0–20)          |
| C-reactive protein            | 4.2 mg/dL     | (0–0.9)         |
| Brain natriuretic protein     | 445 pg/mL     | (0–449)         |
| Alpha-1 antitrypsin           | 2.8 ng/mL     | (0.9–9.0)       |
| Ceruloplasmin                 | 30 mg/dL      | (18–53)         |
| Ferritin                      | 302 ng/dL     | (13–150)        |
| Hepatitis panel (A, B, C)     | Negative      |                 |
| Prothrombin time              | 20.2 sec      | (12.3–14.8)     |
| International normalized ratio| 1.7 sec       | (0.9–1.1)       |
| Partial thromboplastin time   | 38 sec        | (25–36)         |
| Thyroid-stimulating hormone   | 3.9 μU/mL     | (0.4–4.2)       |

a Abnormal results in boldface type.
Heart failure is unlikely based on her normal brain natriuretic peptide level, an ascitic fluid protein level below 2.5 g/dL, and normal results on echocardiography. Nephrotic syndrome is also very unlikely based on the patient’s normal random urine protein-creatinine ratio. Portal vein thrombus and abdominal malignancy are essentially ruled out by the negative results of Doppler abdominal ultrasonography, with normal venous flow and no intra-abdominal mass and coupled with an elevated SAAG.

Although the patient has a history of travel, the incubation period for malaria would not fit the time frame of presentation. Also, she did not have typical malarial symptoms, her rapid malaria test was negative, and a peripheral blood smear for blood parasites was negative. It should be noted, however, that *Plasmodium malariae* infection classically presents with flulike symptoms and can resemble nephrotic syndrome, including peripheral edema, ascites, heavy proteinuria, hypoalbuminemia, and hyperlipidemia.7

Transjugular biopsy confirmed alcoholic hepatitis, despite the patient’s initial denial of alcohol use.

Any patient with cirrhosis and a history of SBP should receive prophylactic antibiotics,8 as should any patient deemed at high risk of SBP. It is indicated in the following patients:
- Patients with cirrhosis and gastrointestinal bleeding9,10
- Patients with cirrhosis and a previous episode of SBP8
- Patients with cirrhosis and an ascitic fluid protein level less than 1.5 g/dL with either impaired renal function (creatinine ≥ 1.2 mg/dL, blood urea nitrogen level ≥ 25 mg/dL, or serum sodium ≤ 130 mmol/L) or liver failure (Child-Pugh score ≥ 9 and a bilirubin ≥ 3 mg/dL)9
- Patients with cirrhosis who are hospitalized for other reasons and have an ascitic protein level < 1.0 g/dL.9

Our patient has no signs or symptoms of gastrointestinal bleeding and no history of SBP. Her ascitic fluid protein level is 1.1 g/dL, and she has normal renal function. However, her Child-Pugh score is 12 (3 points for total bilirubin > 3 mg/dL, 3 points for serum albumin < 2.8 g/dL, 2 points for an INR 1.7 to 2.2, 3 points for moderate ascites, and 1 point for no encephalopathy),
NEW-ONSET ASCITES

To confirm this diagnosis, she subsequently undergoes transjugular liver biopsy, considered the gold standard for the diagnosis of alcoholic hepatitis. During the procedure, the hepatic venous pressure gradient is measured at 18 mm Hg (reference range 1–5 mm Hg), suggestive of portal hypertension. The pathology study shows severe fatty change, active steatohepatitis with ballooning degeneration, easily identifiable Mallory-Denk bodies, and prominent neutrophilic infiltration, as well as extensive bridging fibrosis (Figure 2). These findings point to alcoholic hepatitis.

After the biopsy results, we speak with the patient further about her alcohol habits. At this point, she informs us that she has consumed significant amounts of alcohol since the age of 18 (6 to 12 alcoholic beverages per day, including beer and hard liquor). Therefore, based on this new information, on her jaundice and ascites, and on results of laboratory testing and biopsy, we confirmed our diagnosis of alcoholic hepatitis.

When is drug treatment appropriate for alcoholic hepatitis?

- Model for End-stage Liver Disease (MELD) score greater than 12
- MELD score greater than 15
- Maddrey Discriminant Function score greater than 25
- Maddrey Discriminant Function score greater than 32
- Glasgow score greater than 5
- Glasgow score greater than 7

The best answer is a Maddrey Discriminant Function score greater than 32. A variety of scoring systems have been used to assess the severity of alcoholic hepatitis and to guide treatment, including the Maddrey Discriminant Function score, the MELD score, and the Glasgow score. They share similar laboratory values in their calculations, including prothrombin time (or INR) and total bilirubin. Typically, a Maddrey Discriminant Function score greater than 32, a Glasgow score of greater than 9, or a MELD score greater than 21 is used to determine whether pharmacologic treatment is indicated.

The typical treatment is prednisolone or pentoxifylline. The Lille score is de-
signed to help decide whether to stop corticosteroids after 1 week of administration due to lack of treatment response. It predicts mortality rates within 6 months; a score of 0.45 or less indicates a good prognosis, and corticosteroid therapy should continue for 28 days (Figure 3). Our patient’s discriminant function score is 50, her Glasgow score is 10, and her MELD score is 28; thus, she begins treatment with oral prednisolone. Her Lille score at 1 week is 0.119, indicating a good prognosis, and her corticosteroids are continued for a total of 28 days. It should be highlighted that the most important treatment is abstinence from alcohol. Recent literature suggests that any benefit of prednisolone or pentoxifylline in terms of mortality rates is questionable, and there is evidence that giving both drugs simultaneously may improve mortality rates, but the evidence remains conflicting at this time.

**Figure 3.** Algorithm for the management of alcoholic hepatitis.

#### Clinical signs and symptoms
Acute onset of jaundice (<3 months), fever, ascites, proximal muscle loss, hepatic encephalopathy, enlarged and tender liver, neutrophilic leukocytosis, elevated aspartate aminotransferase-to-alanine aminotransferase ratio (>2:1), hyperbilirubinemia, elevated international normalized ratio with a history of alcohol use.

#### Assess severity
Use the Maddrey Discriminant Function (DF) score, Model for End-Stage Liver Disease (MELD) score, or Glasgow score.

- **DF score ≥ 32, MELD score ≥ 21, Glasgow score ≥ 9**
- **DF score < 32, MELD score < 21, Glasgow score < 9**

#### Consider treatment
Prednisolone 40 mg/day
Or
Pentoxyfylline 400 mg 3 times per day

#### Assess response to prednisolone
Calculate the Lille score at 1 week

- **Lille score ≤ 0.45**
- **Lille score > 0.45**

#### Continue prednisolone
Total duration of 28 days

#### Stop prednisolone

**ALCOHOLIC HEPATITIS**

Alcoholic hepatitis is a clinical syndrome of jaundice and liver failure, often in the setting of heavy alcohol use for decades. The incidence is unknown, but the typical age of presentation is between 40 and 50. The chief sign is a rapid onset of jaundice (<3 months); common signs and symptoms include fever, ascites, proximal muscle loss, and an enlarged, tender liver. Encephalopathy may be seen in severe alcoholic hepatitis.

Our patient is 35 years old. She has jaundice with rapid onset, as well as ascites and a tender liver. The diagnosis of alcoholic hepatitis must take into account the patient’s history, physical examination, and laboratory findings. Until proven otherwise, the diagnosis should be presumed in the following scenario: ascites and jaundice on examination (usually with a duration <3 months); a history of heavy al-
NEW-ONSET ASCITES

1. Sidhu SS, Goyal O, Kishore H, Sidhu S. New paradigms in management of alcoholic hepatitis: a review. Hepatol Int 2017; 11(3):255–267. doi: 10.1007/s12072-017-9790-5

2. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360(26):2758–2769. doi: 10.1056/NEJMoa0905786

3. Bartoloni A, Zammarchi L, Huang LL, Xia HH, Zhu SL. Management of cirrhosis and ascites. N Engl J Med 2004; 350(16):1646–1654. doi:10.1056/NEJMoa035021

4. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis. Hepatology 2015; 61(3):998–1008. doi:10.1002/hep.27816

5. Hernaez R, Hamilton JP. Unexplained ascites. Clin Liver Dis 2016; 20(3):53–56. https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/cld.537

6. Huang LL, Xia HH. Ascitic fluid analysis in the differential diagnosis of ascites: focus on cirrhotic ascites. J Clin Transl Hepatol 2014; 2(1):58–64. doi:10.14218/JCTH.2013.00010

7. Bartoloni A, Zammarchi L. Clinical aspects of uncomplicated and severe malaria. Mediterr J Hematol Infect Dis 2012; 4(1):e2012026. doi:10.4084/MJHID.2012.026

8. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8(1):27–31. pmid:257456

9. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131(4):1049–1056. doi:10.1053/j.gastro.2006.07.010

10. Runyon B. The American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis: update 2012. https://www.aasld.org/sites/default/files/guideline_documents/141020_Guideline_Ascites_4UFb_2015.pdf. Accessed September 4, 2018.

11. Sidhu SS, Goyal O, Kishore H, Sidhu S. New paradigms in management of alcoholic hepatitis: a review. Hepatol Int 2017; 11(3):255–267. doi:10.1007/s12072-017-9790-5

12. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360(26):2758–2769. doi: 10.1056/NEJMoa0905786

13. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75(2):193–199. pmid:352788

14. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54(8):1174–1179. doi:10.1136/gut.2004.050781

15. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41(2):353–358. doi:10.1002/hep.20503

16. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2:2. pmid:11835693

17. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shaliki O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119(6):1637–1648. pmid:11113085

18. Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60(2):255–260. doi:10.1136/gut.2010.224097

19. Thursz MR, Richardson P, Allison M, et al; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372(17):1619–1628. doi:10.1056/NEJMoa1412278

20. Thursz M, Forrest E, Roderick P, et al. The clinical effectiveness and cost-effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. Health Technol Assess 2015; 19(102):1–104. doi:10.3310/hta191020

21. Lee YS, Kim HJ, Kim JH, et al. Treatment of severe alcoholic hepatitis with corticosteroid, pentoxifylline, or dual therapy: a systematic review and meta-analysis. J Clin Gastroenterol 2017; 51(4):364–377. doi:10.1097/MGC.000000000000676

22. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45(6):1348–1354. doi:10.1002/hep.21607